Proteasomes and Several Aspects of Their Heterogeneity Relevant to Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Aug 29

PMID 31456945

Citations 52

Authors

Alexey V Morozov

Vadim L Karpov

Affiliations

Soon will be listed here.

Abstract

The life of every organism is dependent on the fine-tuned mechanisms of protein synthesis and breakdown. The degradation of most intracellular proteins is performed by the ubiquitin proteasome system (UPS). Proteasomes are central elements of the UPS and represent large multisubunit protein complexes directly responsible for the protein degradation. Accumulating data indicate that there is an intriguing diversity of cellular proteasomes. Different proteasome forms, containing different subunits and attached regulators have been described. In addition, proteasomes specific for a particular tissue were identified. Cancer cells are highly dependent on the proper functioning of the UPS in general, and proteasomes in particular. At the same time, the information regarding the role of different proteasome forms in cancer is limited. This review describes the functional and structural heterogeneity of proteasomes, their association with cancer as well as several established and novel proteasome-directed therapeutic strategies.

Citing Articles

CGRPβ suppresses the pathogenesis of ulcerative colitis via the immunoproteasome.

Shibao T, Hase H, Mizokami K, Usui A, Kitae K, Ueda Y Sci Rep. 2025; 15(1):7224.

PMID: 40021701 PMC: 11871240. DOI: 10.1038/s41598-025-91933-w.

Association of Proteasome Activity and Pool Heterogeneity with Markers Determining the Molecular Subtypes of Breast Cancer.

Kondakova I, Sereda E, Sidenko E, Vtorushin S, Vedernikova V, Burov A Cancers (Basel). 2025; 17(1.

PMID: 39796785 PMC: 11720674. DOI: 10.3390/cancers17010159.

Structural Analysis of the 20S Proteasome Using Native Mass Spectrometry and Ultraviolet Photodissociation.

Walker J, Gautam A, Matouschek A, Brodbelt J J Proteome Res. 2024; 23(12):5438-5448.

PMID: 39475212 PMC: 11660092. DOI: 10.1021/acs.jproteome.4c00568.

Limiting 20S proteasome assembly leads to unbalanced nucleo-cytoplasmic distribution of 26S/30S proteasomes and chronic proteotoxicity.

Ruiz-Romero G, Berdun M, Hochstrasser M, Salas-Pino S, Daga R iScience. 2024; 27(11):111095.

PMID: 39473973 PMC: 11513537. DOI: 10.1016/j.isci.2024.111095.

Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers.

Larsson P, Olsson M, Sarathchandra S, Faldt Beding A, Forssell-Aronsson E, Kovacs A Sci Rep. 2024; 14(1):18576.

PMID: 39127727 PMC: 11316778. DOI: 10.1038/s41598-024-62339-x.

References

Parzych K, Saavedra-Garcia P, Valbuena G, Al-Sadah H, Robinson M, Penfold L . The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation. Oncogene. 2019; 38(17):3216-3231. PMC: 6756015. DOI: 10.1038/s41388-018-0651-z. View

Cui Y, Niu M, Zhang X, Zhong Z, Wang J, Pang D . High expression of valosin-containing protein predicts poor prognosis in patients with breast carcinoma. Tumour Biol. 2015; 36(12):9919-27. DOI: 10.1007/s13277-015-3748-9. View

de Verteuil D, Rouette A, Hardy M, Lavallee S, Trofimov A, Gaucher E . Immunoproteasomes shape the transcriptome and regulate the function of dendritic cells. J Immunol. 2014; 193(3):1121-32. DOI: 10.4049/jimmunol.1400871. View

Cloos J, Roeten M, Franke N, Van Meerloo J, Zweegman S, Kaspers G . (Immuno)proteasomes as therapeutic target in acute leukemia. Cancer Metastasis Rev. 2017; 36(4):599-615. PMC: 5721123. DOI: 10.1007/s10555-017-9699-4. View

Cascio P . PA28αβ: the enigmatic magic ring of the proteasome?. Biomolecules. 2014; 4(2):566-84. PMC: 4101498. DOI: 10.3390/biom4020566. View

Kuo C, Goldberg A . Ubiquitinated proteins promote the association of proteasomes with the deubiquitinating enzyme Usp14 and the ubiquitin ligase Ube3c. Proc Natl Acad Sci U S A. 2017; 114(17):E3404-E3413. PMC: 5410784. DOI: 10.1073/pnas.1701734114. View

Erales J, Coffino P . Ubiquitin-independent proteasomal degradation. Biochim Biophys Acta. 2013; 1843(1):216-21. PMC: 3770795. DOI: 10.1016/j.bbamcr.2013.05.008. View

Zaiss D, Standera S, Kloetzel P, Sijts A . PI31 is a modulator of proteasome formation and antigen processing. Proc Natl Acad Sci U S A. 2002; 99(22):14344-9. PMC: 137886. DOI: 10.1073/pnas.212257299. View

Unno M, Mizushima T, Morimoto Y, Tomisugi Y, Tanaka K, Yasuoka N . The structure of the mammalian 20S proteasome at 2.75 A resolution. Structure. 2002; 10(5):609-18. DOI: 10.1016/s0969-2126(02)00748-7. View

10.

Moriishi K, Okabayashi T, Nakai K, Moriya K, Koike K, Murata S . Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein. J Virol. 2003; 77(19):10237-49. PMC: 228494. DOI: 10.1128/jvi.77.19.10237-10249.2003. View

11.

Manasanch E, Orlowski R . Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017; 14(7):417-433. PMC: 5828026. DOI: 10.1038/nrclinonc.2016.206. View

12.

Acs K, Luijsterburg M, Ackermann L, Salomons F, Hoppe T, Dantuma N . The AAA-ATPase VCP/p97 promotes 53BP1 recruitment by removing L3MBTL1 from DNA double-strand breaks. Nat Struct Mol Biol. 2011; 18(12):1345-50. DOI: 10.1038/nsmb.2188. View

13.

Nitta T, Murata S, Sasaki K, Fujii H, Mat Ripen A, Ishimaru N . Thymoproteasome shapes immunocompetent repertoire of CD8+ T cells. Immunity. 2010; 32(1):29-40. DOI: 10.1016/j.immuni.2009.10.009. View

14.

Knowlton J, Johnston S, Whitby F, Realini C, Zhang Z, Rechsteiner M . Structure of the proteasome activator REGalpha (PA28alpha). Nature. 1997; 390(6660):639-43. DOI: 10.1038/37670. View

15.

Matyskiela M, Lander G, Martin A . Conformational switching of the 26S proteasome enables substrate degradation. Nat Struct Mol Biol. 2013; 20(7):781-8. PMC: 3712289. DOI: 10.1038/nsmb.2616. View

16.

Gallagher P, Clowes Candadai S, Gardner R . The requirement for Cdc48/p97 in nuclear protein quality control degradation depends on the substrate and correlates with substrate insolubility. J Cell Sci. 2014; 127(Pt 9):1980-91. PMC: 4004975. DOI: 10.1242/jcs.141838. View

17.

Gillette T, Kumar B, Thompson D, Slaughter C, DeMartino G . Differential roles of the COOH termini of AAA subunits of PA700 (19 S regulator) in asymmetric assembly and activation of the 26 S proteasome. J Biol Chem. 2008; 283(46):31813-22. PMC: 2581596. DOI: 10.1074/jbc.M805935200. View

18.

Kingsbury D, Griffin T, Colbert R . Novel propeptide function in 20 S proteasome assembly influences beta subunit composition. J Biol Chem. 2000; 275(31):24156-62. DOI: 10.1074/jbc.M001742200. View

19.

Osmulski P, Gaczynska M . Atomic force microscopy reveals two conformations of the 20 S proteasome from fission yeast. J Biol Chem. 2000; 275(18):13171-4. DOI: 10.1074/jbc.c901035199. View

20.

Worden E, Padovani C, Martin A . Structure of the Rpn11-Rpn8 dimer reveals mechanisms of substrate deubiquitination during proteasomal degradation. Nat Struct Mol Biol. 2014; 21(3):220-7. DOI: 10.1038/nsmb.2771. View